Featured Research

from universities, journals, and other organizations

Researchers identify two HIV-1 envelope immunogens capable of eliciting antibodies associated with vaccine protection

Date:
January 24, 2014
Source:
Seattle Biomedical Research Institute (Seattle BioMed)
Summary:
Researchers identified two HIV-1 Envelope immunogens that elicit broadly neutralizing antibodies when introduced as a vaccine.

Seattle BioMed researchers identified two HIV-1 Envelope immunogens that elicit broadly neutralizing antibodies when introduced as a vaccine. The study was published online in PLOS One.

The HIV-1 Envelope protein immunogens were derived from an elite neutralizer, an individual with an unusually potent antibody response effective against the majority of HIV subtypes. Seattle BioMed researchers identified two Envelope immunogens that elicited cross-reactive binding antibodies to the variable regions 1 and 2 (V1V2) region of the envelope protein and induced antibodies capable of neutralizing an array of HIV from different subtypes.

"Previous studies have shown that anti-HIV-1 neutralizing antibodies can effectively block infection with HIV-1 if present prior to infection with the virus," said Noah Sather, Ph.D. principal scientist at Seattle BioMed and corresponding author of the study. "In addition, antibodies that target a specific part of the Envelope protein, the V1V2 region, have been shown in clinical trials to be associated with a reduced risk of infection. Thus, the ideal vaccine would introduce immunogens that elicit antibodies both targeted to the V1V2 region of the Envelope protein and capable of providing protection from a wide variety of HIV-1 subtypes."

Follow on studies will focus on further modifying the Envelope immunogens to increase the potency and effectiveness of the vaccine.

The HIV-1 epidemic remains a significant threat to global health, with 2.3 million new HIV-1 infections and 1.6 million AIDS-related deaths each year. While access to anti-retroviral therapies has increased, the best route of defeating the epidemic is still a universally effective HIV-1 vaccine.


Story Source:

The above story is based on materials provided by Seattle Biomedical Research Institute (Seattle BioMed). Note: Materials may be edited for content and length.


Journal Reference:

  1. Sara Carbonetti, Brian G. Oliver, Jolene Glenn, Leonidas Stamatatos, D. Noah Sather. Soluble HIV-1 Envelope Immunogens Derived from an Elite Neutralizer Elicit Cross-Reactive V1V2 Antibodies and Low Potency Neutralizing Antibodies. PLoS ONE, 2014; 9 (1): e86905 DOI: 10.1371/journal.pone.0086905

Cite This Page:

Seattle Biomedical Research Institute (Seattle BioMed). "Researchers identify two HIV-1 envelope immunogens capable of eliciting antibodies associated with vaccine protection." ScienceDaily. ScienceDaily, 24 January 2014. <www.sciencedaily.com/releases/2014/01/140124101737.htm>.
Seattle Biomedical Research Institute (Seattle BioMed). (2014, January 24). Researchers identify two HIV-1 envelope immunogens capable of eliciting antibodies associated with vaccine protection. ScienceDaily. Retrieved October 1, 2014 from www.sciencedaily.com/releases/2014/01/140124101737.htm
Seattle Biomedical Research Institute (Seattle BioMed). "Researchers identify two HIV-1 envelope immunogens capable of eliciting antibodies associated with vaccine protection." ScienceDaily. www.sciencedaily.com/releases/2014/01/140124101737.htm (accessed October 1, 2014).

Share This



More Health & Medicine News

Wednesday, October 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Some Positive Ebola News: Outbreak 'Contained' In Nigeria

Some Positive Ebola News: Outbreak 'Contained' In Nigeria

Newsy (Sep. 30, 2014) The CDC says a new case of Ebola has not been reported in Nigeria for more than 21 days, leading to hopes the outbreak might be nearing its end. Video provided by Newsy
Powered by NewsLook.com
UN Ebola Mission Head: Immediate Action Is Crucial

UN Ebola Mission Head: Immediate Action Is Crucial

AFP (Sep. 30, 2014) The newly appointed head of the United Nations Mission for Ebola Emergency Response (UNMEER), Anthony Banbury, outlines operations to tackle the virus. Duration: 00:39 Video provided by AFP
Powered by NewsLook.com
CDC Confirms First Case of Ebola in US

CDC Confirms First Case of Ebola in US

AP (Sep. 30, 2014) The CDC has confirmed the first diagnosed case of Ebola in the United States. The patient is being treated at a Dallas hospital after traveling earlier this month from Liberia. (Sept. 30) Video provided by AP
Powered by NewsLook.com
New Breast Cancer Drug Extends Lives In Clinical Trial

New Breast Cancer Drug Extends Lives In Clinical Trial

Newsy (Sep. 30, 2014) In a clinical trial, breast cancer patients lived an average of 15 months longer when they received new drug Perjeta along with Herceptin. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins